VITRUVIA MEDICAL AG |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.4 EUR | -20.00% |
|
-20.00% | -66.67% |
| 2023 | Vitruvia Medical AG Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
| 2022 | Vitruvia Medical AG announced that it expects to receive CHF 2.2 million in funding | CI |
Valuation
| Fiscal Period: December | 2021 | 2022 |
|---|---|---|
| Capitalization 1 | 28.32 | 4.071 |
| Enterprise Value (EV) 1 | 28.27 | 4.914 |
| P/E ratio | - | -2.62 x |
| Yield | - | - |
| Capitalization / Revenue | 14.4 x | 2.67 x |
| EV / Revenue | 14.4 x | 3.22 x |
| EV / EBITDA | -36.4 x | -5.39 x |
| EV / FCF | - | - |
| FCF Yield | - | - |
| Price to Book | - | -2.44 x |
| Nbr of stocks (in thousands) | 1,770 | 1,770 |
| Reference price 2 | 16.00 | 2.300 |
| Announcement Date | 25/06/23 | 25/06/23 |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 |
|---|---|---|---|
| Net sales 1 | 5.772 | 1.966 | 1.526 |
| EBITDA 1 | -0.9605 | -0.7757 | -0.9121 |
| EBIT 1 | -1.313 | -1.128 | -1.344 |
| Operating Margin | -22.74% | -57.36% | -88.12% |
| Earnings before Tax (EBT) 1 | -1.496 | -8.133 | -1.467 |
| Net income 1 | -1.545 | -8.132 | -1.485 |
| Net margin | -26.76% | -413.55% | -97.31% |
| EPS 2 | -1.046 | - | -0.8774 |
| Free Cash Flow | - | - | - |
| FCF margin | - | - | - |
| FCF Conversion (EBITDA) | - | - | - |
| FCF Conversion (Net income) | - | - | - |
| Dividend per Share | - | - | - |
| Announcement Date | 03/05/21 | 25/06/23 | 25/06/23 |
1EUR in Million2EUR
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 |
|---|---|---|---|
| Net Debt 1 | - | - | 0.84 |
| Net Cash position 1 | 0.71 | 0.05 | - |
| Leverage (Debt/EBITDA) | - | - | -0.9244 x |
| Free Cash Flow | - | - | - |
| ROE (net income / shareholders' equity) | - | -435% | 170% |
| ROA (Net income/ Total Assets) | - | -13.8% | -39.5% |
| Assets 1 | - | 58.87 | 3.762 |
| Book Value Per Share 2 | 2.630 | - | -0.9400 |
| Cash Flow per Share 2 | 0.4800 | - | 0.1300 |
| Capex 1 | 2.91 | - | - |
| Capex / Sales | 50.44% | - | - |
| Announcement Date | 03/05/21 | 25/06/23 | 25/06/23 |
1EUR in Million2EUR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -66.67% | 987K | |
| +4.63% | 32.15B | |
| +18.56% | 7.41B | |
| +20.94% | 3.85B | |
| -17.01% | 3.13B | |
| -22.16% | 1.25B | |
| -31.01% | 1.17B | |
| +4.40% | 926M | |
| -34.81% | 911M | |
| -25.64% | 842M |
- Stock Market
- Equities
- 991 Stock
- Financials Vitruvia Medical AG
